The treatment was administered in patients with recurrent or persistent refractory HER2+ breast cancer suggested a 10% increase in disease-free survival (DFS) between a cohort of HLA A*02/A*03 patients given E75 and GM-CSF and the negative control group consisting of patients of other HLA-types who received no treatment [19]. Here, ERBB2 is linked to breast cancer.